News

Treatment shown to ease symptoms, reduce disability, improve quality of lifeAmvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability,…

Detecting heart failure in its earliest stages has long been a challenge for clinicians, particularly when the cause is a rare and often misdiagnosed protein…

Cardiac MRI tissue characterization can detect early, low-burden transthyretin cardiac amyloidosis and accurately distinguish it from similar conditions, a study…

Anumana has received FDA approval for its ECG-AI algorithm designed to support the diagnosis of cardiac amyloidosis at the point of care. This makes it the first…

New analyses from the phase 3 HELIOS-B trial (NCT04153149) offer a more in-depth picture of vutrisiran's (Amvuttra; Alnylam) impact in transthyretin amyloid…

AbstractBackgroundTransthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided…

Anumana, a Massachusetts-based artificial intelligence (AI) company co-founded by nference and Mayo Clinic, has received U.S. Food and Drug Administration (FDA)…

Anumana has received FDA approval for its ECG-AI algorithm designed to support the diagnosis of cardiac amyloidosis at the point of care. This makes it the first…

Anumana, a leader in cardiovascular AI, announced U.S. Food and Drug Administration (FDA) clearance of its ECG-AI algorithm for cardiac amyloidosis (CA) – the first…

This study is testing an investigational gene-editing treatment designed to reduce the production of transthyretin (TTR), a protein that causes amyloid buildup in…